Next Science Ltd
NXS
Company Profile
Business description
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with efficacy in eradicating both biofilm-based and free-floating bacteria. Its products include Bactisure, XEPERIENCE and BLASTX. The company derives revenue from North America, New Zealand, and Australia.
Contact
264-278 George Street
Level 14, Australia Square
HWL Ebsworth
SydneyNSW2000
AUST: +61 291887772
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
stocks
Looking for growth outside the ASX100
Small caps have outperformed blue chips this year. Here’s some opportunities outside the ASX100.
stocks
Netflix and Warner Bros. Discovery: Surprisingly high merger price alters shareholder value for both
Our view on the blockbuster merger.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,900.30 | 11.40 | 0.13% |
| CAC 40 | 8,114.74 | 7.29 | -0.09% |
| DAX 40 | 24,028.14 | 146.11 | 0.61% |
| Dow JONES (US) | 47,954.99 | 104.05 | 0.22% |
| FTSE 100 | 9,667.01 | 43.86 | -0.45% |
| HKSE | 25,796.96 | 288.12 | -1.10% |
| NASDAQ | 23,578.13 | 72.99 | 0.31% |
| Nikkei 225 | 50,406.05 | 85.82 | -0.17% |
| NZX 50 Index | 13,491.05 | 7.06 | 0.05% |
| S&P 500 | 6,870.40 | 13.28 | 0.19% |
| S&P/ASX 200 | 8,608.40 | 12.80 | 0.15% |
| SSE Composite Index | 3,927.19 | 24.39 | 0.62% |